Immodulon 
Welcome,         Profile    Billing    Logout  
 2 Products   21 Diseases  2 Products   4 Trials   96 News 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IMM-101 / Immodulon
COV-IMMUNO, NCT04442048: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

Active, not recruiting
3
195
Canada
IMM-101, Observation
Canadian Cancer Trials Group, Immodulon Therapeutics Ltd, BioCan Rx, Canadian Cancer Society (CCS), ATGen Canada Inc, Canadian Centre for Applied Research in Cancer Control (ARCC), Ontario Institute for Cancer Research
Cancer, Covid-19
05/24
06/25
2019-000216-29: Safety and efficacy of adding immunotherapy to the standard of care for locally advanced pancreatic cancer patients (LAPC-2 trial).

Not yet recruiting
2
38
Europe
IMM-101, Suspension for injection
Erasmus MC, Erasmus MC
Locally advanced pancreatic cancer, Locally advanced pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
2020-003945-13: Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer(MEPANC-1)

Ongoing
2
100
Europe
IMM-101, Suspension for injection
Erasmus MC, Erasmus MC, Immodulon Therapeutics
Limited metastatic pancreatic cancer, metastatic pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
2020-002715-21: Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study

Not yet recruiting
2
80
Europe
Atezolizumab, IMM-101, L01XC32, Concentrate for solution for infusion, Suspension for injection, Tecentriq (R)
AIO-Studien-gGmbH, F. Hoffmann-La Roche Ltd, Immodulon Therapeutics Ltd.
Patients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (sub-study), patients with stage III colon or rectum cancer who are ineligible or refuse oxaliplatin-based chemotherape after surgical removal of the tumor (main study) oder the surgery is planned (sub-study), Diseases [C] - Cancer [C04]
 
 
PRIMUS006, NCT06498518: A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer

Recruiting
2
50
Europe
IMM-101, Pembrolizumab, Gemcitabine
Karen Carty, NHS Greater Glasgow and Clyde, University of Glasgow
Neoplasms Pancreatic
06/27
12/27
ANTONIO, NCT05118724 / 2020-002715-21: Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Active, not recruiting
2
80
Europe
Atezolizumab, Tecentriq, IMM-101
AIO-Studien-gGmbH, Roche Pharma AG, Immodulon Therapeutics Ltd
Colorectal Cancer
04/27
04/27
NCT04137822: Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

No Longer Available
N/A
Europe
IMM-101, Heat-killed whole cell M. obuense
Impatients N.V. trading as myTomorrows, Immodulon Therapeutics Ltd
Pancreas Cancer, Pancreatic Cancer, Pancreatic Cancer Stage IV, Pancreatic Cancer Stage III
 
 
IMM-201 / Immodulon
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IMM-101 / Immodulon
COV-IMMUNO, NCT04442048: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

Active, not recruiting
3
195
Canada
IMM-101, Observation
Canadian Cancer Trials Group, Immodulon Therapeutics Ltd, BioCan Rx, Canadian Cancer Society (CCS), ATGen Canada Inc, Canadian Centre for Applied Research in Cancer Control (ARCC), Ontario Institute for Cancer Research
Cancer, Covid-19
05/24
06/25
2019-000216-29: Safety and efficacy of adding immunotherapy to the standard of care for locally advanced pancreatic cancer patients (LAPC-2 trial).

Not yet recruiting
2
38
Europe
IMM-101, Suspension for injection
Erasmus MC, Erasmus MC
Locally advanced pancreatic cancer, Locally advanced pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
2020-003945-13: Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer(MEPANC-1)

Ongoing
2
100
Europe
IMM-101, Suspension for injection
Erasmus MC, Erasmus MC, Immodulon Therapeutics
Limited metastatic pancreatic cancer, metastatic pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
2020-002715-21: Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study

Not yet recruiting
2
80
Europe
Atezolizumab, IMM-101, L01XC32, Concentrate for solution for infusion, Suspension for injection, Tecentriq (R)
AIO-Studien-gGmbH, F. Hoffmann-La Roche Ltd, Immodulon Therapeutics Ltd.
Patients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (sub-study), patients with stage III colon or rectum cancer who are ineligible or refuse oxaliplatin-based chemotherape after surgical removal of the tumor (main study) oder the surgery is planned (sub-study), Diseases [C] - Cancer [C04]
 
 
PRIMUS006, NCT06498518: A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer

Recruiting
2
50
Europe
IMM-101, Pembrolizumab, Gemcitabine
Karen Carty, NHS Greater Glasgow and Clyde, University of Glasgow
Neoplasms Pancreatic
06/27
12/27
ANTONIO, NCT05118724 / 2020-002715-21: Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Active, not recruiting
2
80
Europe
Atezolizumab, Tecentriq, IMM-101
AIO-Studien-gGmbH, Roche Pharma AG, Immodulon Therapeutics Ltd
Colorectal Cancer
04/27
04/27
NCT04137822: Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

No Longer Available
N/A
Europe
IMM-101, Heat-killed whole cell M. obuense
Impatients N.V. trading as myTomorrows, Immodulon Therapeutics Ltd
Pancreas Cancer, Pancreatic Cancer, Pancreatic Cancer Stage IV, Pancreatic Cancer Stage III
 
 
IMM-201 / Immodulon
No trials found

Download Options